<DOC>
	<DOCNO>NCT03033329</DOCNO>
	<brief_summary>A Phase 1 study safety , tolerability , pharmacokinetics new oxazolidinone antibiotic . In Part 1 cohort healthy adult participate single dose escalation study increase intravenous dos MRX-4 . In Part 2 cohort healthy adult participate multiple dose escalation study increase intravenous dos MRX-4 give twice daily ten day . Part 3 crossover study oral MRX-4 versus comparable intravenous dose MRX-4 determine bioavailability .</brief_summary>
	<brief_title>Single Dose Escalation Multiple Dose Escalation Trial Intravenous Formulation MRX-4</brief_title>
	<detailed_description />
	<criteria>Healthy subject Underlying hepatic , renal , metabolic , hematologic , cardiovascular , immunologic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>